Key result
Central administration of 0.2 and 2.0 nmol atriopeptin III inhibited saline intake in conscious, salt-depleted rats in a dose-related and long-lasting manner.
Why the study?
Does central administration of atriopeptin III inhibit saline intake in salt-depleted rats?
Does central administration of atriopeptin III inhibit saline intake in salt-depleted rats?
Central administration of atrial natriuretic factor (atriopeptin III) inhibits saline preference in rats, suggesting a central nervous system role in fluid volume control.
May implicate central ANP in rodent volume control; leaves open any human relevance.
Atrial natriuretic factors (ANFs), produced in myocytes of mammalian atria, exert potent natriuretic and diuretic actions in the kidney as well as a variety of other actions coordinated to normalize extracellular fluid volume. Recently, ANF-like immunoreactivity has been detected in the hypothalamus of the rat, and central administration of ANF has been shown to block dehydration-induced water intake. We describe here the ability of 0.2 and 2.0 nmol atriopeptin III to inhibit saline intake when infused into the third ventricle of conscious, salt-depleted rats; an effect that was dose-related and long-lasting (24 h). These studies provide further evidence for a central nervous system action of ANF, which, together with its established renal and adrenal actions, might be an important feature of the coordinated physiological control of fluid volume.
No takes yet. Share an insight, caveat, or question.
Antunes‐Rodrigues et al. (1986) studied Salt depletion. Atriopeptin III was evaluated on Saline intake. Central administration of 0.2 and 2.0 nmol atriopeptin III inhibited saline intake in conscious, salt-depleted rats in a dose-related and long-lasting manner.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: